Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma

Akihide Fujimoto, Hiroya Takeuchi, Bret Taback, Eddy C. Hsueh, David Elashoff, Donald L. Morton, Dave S B Hoon

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to chemotherapy and radiotherapy. This resistance may be in part due to inhibition of apoptosis. Apoptotic protease activating factor-1 (APAF-1), a candidate tumor suppressor gene, mediates p53-induced apoptosis, and its loss promotes oncogenic transformation. To determine whether loss of the APAF-1 locus influences tumor progression, we assessed loss of heterozygosity microsatellites on the APAF-1 locus (12q22-23) in 62 primary and 112 metastatic melanomas. We discovered that frequency of allelic imbalance was significantly higher in metastatic tumors (n = 36 of 98; 37%) than in primary melanomas (n = 10 of 54; 19%; P = 0.02). In metastatic melanomas, APAF-1 loss significantly correlated with a worse prognosis (P < 0.05) in the patients, and its loss during melanoma tumor progression suggests that APAF-1 is a tumor suppressor gene. Furthermore, loss of heterozygosity was frequent in the 12q22-23 chromosome region centromeric to the APAF-1 locus suggesting that other tumor-related genes may be present in the 12q22-23 region. In summary, the study demonstrates that allelic imbalance in the 12q22-23 region is a genomic surrogate of poor disease outcome for cutaneous melanoma patients.

Original languageEnglish
Pages (from-to)2245-2250
Number of pages6
JournalCancer Research
Volume64
Issue number6
DOIs
Publication statusPublished - 2004 Mar 15
Externally publishedYes

Fingerprint

Apoptotic Protease-Activating Factor 1
Allelic Imbalance
Melanoma
Skin
Loss of Heterozygosity
Neoplasms
Tumor Suppressor Genes
Apoptosis
Microsatellite Repeats
Radiotherapy
Chromosomes
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fujimoto, A., Takeuchi, H., Taback, B., Hsueh, E. C., Elashoff, D., Morton, D. L., & Hoon, D. S. B. (2004). Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma. Cancer Research, 64(6), 2245-2250. https://doi.org/10.1158/0008-5472.CAN-03-2932

Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma. / Fujimoto, Akihide; Takeuchi, Hiroya; Taback, Bret; Hsueh, Eddy C.; Elashoff, David; Morton, Donald L.; Hoon, Dave S B.

In: Cancer Research, Vol. 64, No. 6, 15.03.2004, p. 2245-2250.

Research output: Contribution to journalArticle

Fujimoto, A, Takeuchi, H, Taback, B, Hsueh, EC, Elashoff, D, Morton, DL & Hoon, DSB 2004, 'Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma', Cancer Research, vol. 64, no. 6, pp. 2245-2250. https://doi.org/10.1158/0008-5472.CAN-03-2932
Fujimoto, Akihide ; Takeuchi, Hiroya ; Taback, Bret ; Hsueh, Eddy C. ; Elashoff, David ; Morton, Donald L. ; Hoon, Dave S B. / Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma. In: Cancer Research. 2004 ; Vol. 64, No. 6. pp. 2245-2250.
@article{ba29a3b0b2e84ad499b3330d3a148889,
title = "Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma",
abstract = "Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to chemotherapy and radiotherapy. This resistance may be in part due to inhibition of apoptosis. Apoptotic protease activating factor-1 (APAF-1), a candidate tumor suppressor gene, mediates p53-induced apoptosis, and its loss promotes oncogenic transformation. To determine whether loss of the APAF-1 locus influences tumor progression, we assessed loss of heterozygosity microsatellites on the APAF-1 locus (12q22-23) in 62 primary and 112 metastatic melanomas. We discovered that frequency of allelic imbalance was significantly higher in metastatic tumors (n = 36 of 98; 37{\%}) than in primary melanomas (n = 10 of 54; 19{\%}; P = 0.02). In metastatic melanomas, APAF-1 loss significantly correlated with a worse prognosis (P < 0.05) in the patients, and its loss during melanoma tumor progression suggests that APAF-1 is a tumor suppressor gene. Furthermore, loss of heterozygosity was frequent in the 12q22-23 chromosome region centromeric to the APAF-1 locus suggesting that other tumor-related genes may be present in the 12q22-23 region. In summary, the study demonstrates that allelic imbalance in the 12q22-23 region is a genomic surrogate of poor disease outcome for cutaneous melanoma patients.",
author = "Akihide Fujimoto and Hiroya Takeuchi and Bret Taback and Hsueh, {Eddy C.} and David Elashoff and Morton, {Donald L.} and Hoon, {Dave S B}",
year = "2004",
month = "3",
day = "15",
doi = "10.1158/0008-5472.CAN-03-2932",
language = "English",
volume = "64",
pages = "2245--2250",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma

AU - Fujimoto, Akihide

AU - Takeuchi, Hiroya

AU - Taback, Bret

AU - Hsueh, Eddy C.

AU - Elashoff, David

AU - Morton, Donald L.

AU - Hoon, Dave S B

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to chemotherapy and radiotherapy. This resistance may be in part due to inhibition of apoptosis. Apoptotic protease activating factor-1 (APAF-1), a candidate tumor suppressor gene, mediates p53-induced apoptosis, and its loss promotes oncogenic transformation. To determine whether loss of the APAF-1 locus influences tumor progression, we assessed loss of heterozygosity microsatellites on the APAF-1 locus (12q22-23) in 62 primary and 112 metastatic melanomas. We discovered that frequency of allelic imbalance was significantly higher in metastatic tumors (n = 36 of 98; 37%) than in primary melanomas (n = 10 of 54; 19%; P = 0.02). In metastatic melanomas, APAF-1 loss significantly correlated with a worse prognosis (P < 0.05) in the patients, and its loss during melanoma tumor progression suggests that APAF-1 is a tumor suppressor gene. Furthermore, loss of heterozygosity was frequent in the 12q22-23 chromosome region centromeric to the APAF-1 locus suggesting that other tumor-related genes may be present in the 12q22-23 region. In summary, the study demonstrates that allelic imbalance in the 12q22-23 region is a genomic surrogate of poor disease outcome for cutaneous melanoma patients.

AB - Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to chemotherapy and radiotherapy. This resistance may be in part due to inhibition of apoptosis. Apoptotic protease activating factor-1 (APAF-1), a candidate tumor suppressor gene, mediates p53-induced apoptosis, and its loss promotes oncogenic transformation. To determine whether loss of the APAF-1 locus influences tumor progression, we assessed loss of heterozygosity microsatellites on the APAF-1 locus (12q22-23) in 62 primary and 112 metastatic melanomas. We discovered that frequency of allelic imbalance was significantly higher in metastatic tumors (n = 36 of 98; 37%) than in primary melanomas (n = 10 of 54; 19%; P = 0.02). In metastatic melanomas, APAF-1 loss significantly correlated with a worse prognosis (P < 0.05) in the patients, and its loss during melanoma tumor progression suggests that APAF-1 is a tumor suppressor gene. Furthermore, loss of heterozygosity was frequent in the 12q22-23 chromosome region centromeric to the APAF-1 locus suggesting that other tumor-related genes may be present in the 12q22-23 region. In summary, the study demonstrates that allelic imbalance in the 12q22-23 region is a genomic surrogate of poor disease outcome for cutaneous melanoma patients.

UR - http://www.scopus.com/inward/record.url?scp=1542510618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542510618&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-2932

DO - 10.1158/0008-5472.CAN-03-2932

M3 - Article

C2 - 15026369

AN - SCOPUS:1542510618

VL - 64

SP - 2245

EP - 2250

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -